Based on the inspiring results of CHOICE-01, this study was conducted to compare the cost-effectiveness of toripalimab plus chemotherapy with chemotherapy alone for patients with advanced NSCLC without an EGFR/ALK mutation from the Chinese payer’s perspective. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.